Area of research
Oncology · Surgery
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Intraperitoneal and Appendiceal Malignancies, Colorectal Cancer Surgical Treatments, and Cancer Immunotherapy and Biomarkers.
High prevalence of <i>KRAS</i> and <i>GNAS</i> mutations in pseudomyxoma peritonei underscores opportunities for targeted therapeutic strategies.
Peritoneal Surface Oncology surgery: Reflections on key determinants of success for female surgeons in this challenging discipline.
Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data.
Limited clinical utility of mutation-based circulating tumor DNA detection in pseudomyxoma peritonei
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer.
Early detection of deep pelvic surgical site infection by microdialysis after abdominoperineal resection for locally advanced rectal cancer.
Data from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
Supplementary Figures from Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma
A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal Cancer
Hyperthermic intraperitoneal chemotherapy in colorectal cancer
First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial.
The empty pelvis syndrome: a core data set from the PelvEx collaborative.
Hyperthermic intraperitoneal chemotherapy in colorectal cancer.
Complete response of metastatic microsatellite-stable <i>BRAF</i> V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade.
Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer.
Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma.
Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments.
Beating the empty pelvis syndrome: the PelvEx Collaborative core outcome set study protocol.
Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Supplementary Figures from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
Data from Intraperitoneal paclitaxel is a safe and effective therapeutic strategy for treating mucinous appendiceal adenocarcinoma
A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models.
Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer.
Intraperitoneal Paclitaxel Is a Safe and Effective Therapeutic Strategy for Treating Mucinous Appendiceal Adenocarcinoma.
A <i>PRRX1</i> Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases.
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification.
Empty pelvis syndrome: PelvEx Collaborative guideline proposal.
Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei.